|
1
|
Pulte D and Brenner H: Changes in survival
in head and neck cancers in the late 20th and early 21st century: A
period analysis. Oncologist. 15:994–1001. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lam L, Logan RM and Luke C:
Epidemiological analysis of tongue cancer in South Australia for
the 24-year period, 1977–2001. Aust Dent J. 51:16–22. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Beasley NJ, Prevo R, Banerji S, Leek RD,
Moore J, van Trappen P, Cox G, Harris AL and Jackson DG:
Intratumoral lymphangiogenesis and lymph node metastasis in head
and neck cancer. Cancer Res. 62:1315–1320. 2002.PubMed/NCBI
|
|
4
|
Patel V, Marsh CA, Dorsam RT, Mikelis CM,
Masedunskas A, Amornphimoltham P, Nathan CA, Singh B, Weigert R,
Molinolo AA, et al: Decreased lymphangiogenesis and lymph node
metastasis by mTOR inhibition in head and neck cancer. Cancer Res.
71:7103–7112. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Roepman P, Kemmeren P, Wessels LF,
Slootweg PJ and Holstege FC: Multiple robust signatures for
detecting lymph node metastasis in head and neck cancer. Cancer
Res. 66:2361–2366. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Duan Z, Foster R, Bell DA, Mahoney J,
Wolak K, Vaidya A, Hampel C, Lee H and Seiden MV: Signal
transducers and activators of transcription 3 pathway activation in
drug-resistant ovarian cancer. Clin Cancer Res. 12:5055–5063. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Giraud S, Bienvenu F, Avril S, Gascan H,
Heery DM and Coqueret O: Functional interaction of STAT3
transcription factor with the coactivator NcoA/SRC1a. J Biol Chem.
277:8004–8011. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Nakashima K, Yanagisawa M, Arakawa H,
Kimura N, Hisatsune T, Kawabata M, Miyazono K and Taga T:
Synergistic signaling in fetal brain by STAT3-Smad1 complex bridged
by p300. Science. 284:479–482. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Margueron R and Reinberg D: The Polycomb
complex PRC2 and its mark in life. Nature. 469:343–349. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ciferri C, Lander GC, Maiolica A, Herzog
F, Aebersold R and Nogales E: Molecular architecture of human
polycomb repressive complex 2. Elife. 1:e000052012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lin YW, Ren LL, Xiong H, Du W, Yu YN, Sun
TT, Weng YR, Wang ZH, Wang JL, Wang YC, et al: Role of STAT3 and
vitamin D receptor in EZH2-mediated invasion of human colorectal
cancer. J Pathol. 230:277–290. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kim E, Kim M, Woo DH, Shin Y, Shin J,
Chang N, Oh YT, Kim H, Rheey J, Nakano I, et al: Phosphorylation of
EZH2 activates STAT3 signaling via STAT3 methylation and promotes
tumorigenicity of glioblastoma stem-like cells. Cancer Cell.
23:839–852. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Methylation by EZH2 activates STAT3 in
glioblastoma. Cancer Discov. 3:OF212013.PubMed/NCBI
|
|
14
|
Xue X, Zhang Y, Zhi Q, Tu M, Xu Y, Sun J,
Wei J, Lu Z, Miao Y and Gao W: MiR200-upregulated Vasohibin 2
promotes the malignant transformation of tumors by inducing
epithelial-mesenchymal transition in hepatocellular carcinoma. Cell
Commun Signal. 12:622014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sossey-Alaoui K, Bialkowska K and Plow EF:
The miR200 family of microRNAs regulates WAVE3-dependent cancer
cell invasion. J Biol Chem. 284:33019–33029. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sun N, Zhang Q, Xu C, Zhao Q, Ma Y, Lu X,
Wang L and Li W: Molecular regulation of ovarian cancer cell
invasion. Tumour Biol. 35:11359–11366. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Holzner S, Senfter D, Stadler S,
Staribacher A, Nguyen CH, Gaggl A, Geleff S, Huttary N, Krieger S,
Jäger W, et al: Colorectal cancer cell-derived microRNA200
modulates the resistance of adjacent blood endothelial barriers in
vitro. Oncol Rep. 36:3065–3071. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xiao P, Liu W and Zhou H: miR-200b
inhibits migration and invasion in non-small cell lung cancer cells
via targeting FSCN1. Mol Med Rep. 14:1835–1840. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yuan D, Xia H, Zhang Y, Chen L, Leng W,
Chen T, Chen Q, Tang Q, Mo X, Liu M, et al: P-Akt/miR 200 signaling
regulates epithelial-mesenchymal transition, migration and invasion
in circulating gastric tumor cells. Int J Oncol. 45:2430–2438.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chen J, Wang L, Matyunina LV, Hill CG and
McDonald JF: Overexpression of miR-429 induces
mesenchymal-to-epithelial transition (MET) in metastatic ovarian
cancer cells. Gynecol Oncol. 121:200–205. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gregory PA, Bert AG, Paterson EL, Barry
SC, Tsykin A, Farshid G, Vadas MA, Khew-Goodall Y and Goodall GJ:
The miR-200 family and miR-205 regulate epithelial to mesenchymal
transition by targeting ZEB1 and SIP1. Nat Cell Biol. 10:593–601.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Park SM, Gaur AB, Lengyel E and Peter ME:
The miR-200 family determines the epithelial phenotype of cancer
cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes
Dev. 22:894–907. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ning X, Shi Z, Liu X, Zhang A, Han L,
Jiang K, Kang C and Zhang Q: DNMT1 and EZH2 mediated methylation
silences the microRNA-200b/a/429 gene and promotes tumor
progression. Cancer Lett. 359:198–205. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
25
|
Lee TK, Poon RT, Wo JY, Ma S, Guan XY,
Myers JN, Altevogt P and Yuen AP: Lupeol suppresses
cisplatin-induced nuclear factor-kappaB activation in head and neck
squamous cell carcinoma and inhibits local invasion and nodal
metastasis in an orthotopic nude mouse model. Cancer Res.
67:8800–8809. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Scuto A, Kujawski M, Kowolik C, Krymskaya
L, Wang L, Weiss LM, Digiusto D, Yu H, Forman S and Jove R: STAT3
inhibition is a therapeutic strategy for ABC-like diffuse large
B-cell lymphoma. Cancer Res. 71:3182–3188. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Fiskus W, Wang Y, Sreekumar A, Buckley KM,
Shi H, Jillella A, Ustun C, Rao R, Fernandez P, Chen J, et al:
Combined epigenetic therapy with the histone methyltransferase EZH2
inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor
panobinostat against human AML cells. Blood. 114:2733–2743. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Feldman AT and Wolfe D: Tissue processing
and hematoxylin and eosin staining. Methods Mol Biol. 1180:31–43.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yang H, Yamazaki T, Pietrocola F, Zhou H,
Zitvogel L, Ma Y and Kroemer G: STAT3 inhibition enhances the
therapeutic efficacy of immunogenic chemotherapy by stimulating
type 1 interferon production by cancer cells. Cancer Res.
75:3812–3822. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sharma V, Purkait S, Takkar S, Malgulwar
PB, Kumar A, Pathak P, Suri V, Sharma MC, Suri A, Kale SS, et al:
Analysis of EZH2: micro-RNA network in low and high grade
astrocytic tumors. Brain Tumor Pathol. 33:117–128. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chen J, Lan T, Zhang W, Dong L, Kang N,
Zhang S, Fu M, Liu B, Liu K and Zhan Q: Feed-forward reciprocal
activation of PAFR and STAT3 regulates epithelial-mesenchymal
transition in non-small cell lung cancer. Cancer Res. 75:4198–4210.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Loncle C, Bonjoch L, Folch-Puy E,
Lopez-Millan MB, Lac S, Molejon MI, Chuluyan E, Cordelier P, Dubus
P, Lomberk G, et al: IL17 Functions through the Novel
REG3β-JAK2-STAT3 inflammatory pathway to promote the transition
from chronic pancreatitis to pancreatic cancer. Cancer Res.
75:4852–4862. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Baumgart S, Chen NM, Siveke JT, König A,
Zhang JS, Singh SK, Wolf E, Bartkuhn M, Esposito I, Heßmann E, et
al: Inflammation-induced NFATc1-STAT3 transcription complex
promotes pancreatic cancer initiation by KrasG12D. Cancer Discov.
4:688–701. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kesselring R, Glaesner J, Hiergeist A,
Naschberger E, Neumann H, Brunner SM, Wege AK, Seebauer C, Köhl G,
Merkl S, et al: IRAK-M expression in tumor cells supports
colorectal cancer progression through reduction of antimicrobial
defense and stabilization of STAT3. Cancer Cell. 29:684–696. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Fan TF, Bu LL, Wang WM, Ma SR, Liu JF,
Deng WW, Mao L, Yu GT, Huang CF, Liu B, et al: Tumor growth
suppression by inhibiting both autophagy and STAT3 signaling in
HNSCC. Oncotarget. 6:43581–43593. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhou X, Ren Y, Liu A, Han L, Zhang K, Li
S, Li P, Li P, Kang C, Wang X, et al: STAT3 inhibitor WP1066
attenuates miRNA-21 to suppress human oral squamous cell carcinoma
growth in vitro and in vivo. Oncol Rep. 31:2173–2180. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhou X, Ren Y, Liu A, Jin R, Jiang Q,
Huang Y, Kong L, Wang X and Zhang L: WP1066 sensitizes oral
squamous cell carcinoma cells to cisplatin by targeting
STAT3/miR-21 axis. Sci Rep. 4:74612014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhou X, Ren Y, Kong L, Cai G, Sun S, Song
W, Wang Y, Jin R, Qi L, Mei M, et al: Targeting EZH2 regulates
tumor growth and apoptosis through modulating mitochondria
dependent cell-death pathway in HNSCC. Oncotarget. 6:33720–33732.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Dasgupta M, Dermawan JK, Willard B and
Stark GR: STAT3-driven transcription depends upon the dimethylation
of K49 by EZH2. Proc Natl Acad Sci USA. 112:3985–3990. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Pan YM, Wang CG, Zhu M, Xing R, Cui JT, Li
WM, Yu DD, Wang SB, Zhu W, Ye YJ, et al: STAT3 signaling drives
EZH2 transcriptional activation and mediates poor prognosis in
gastric cancer. Mol Cancer. 15:792016. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Wiklund ED, Bramsen JB, Hulf T, Dyrskjøt
L, Ramanathan R, Hansen TB, Villadsen SB, Gao S, Ostenfeld MS,
Borre M, et al: Coordinated epigenetic repression of the miR-200
family and miR-205 in invasive bladder cancer. Int J Cancer.
128:1327–1334. 2011. View Article : Google Scholar
|
|
42
|
Manavalan TT, Teng Y, Litchfield LM,
Muluhngwi P, Al-Rayyan N and Klinge CM: Reduced expression of
miR-200 family members contributes to antiestrogen resistance in
LY2 human breast cancer cells. PLoS One. 8:e623342013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Izumchenko E, Chang X, Michailidi C,
Kagohara L, Ravi R, Paz K, Brait M, Hoque MO, Ling S, Bedi A, et
al: The TGFβ-miR200-MIG6 pathway orchestrates the EMT-associated
kinase switch that induces resistance to EGFR inhibitors. Cancer
Res. 74:3995–4005. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Davalos V, Moutinho C, Villanueva A, Boque
R, Silva P, Carneiro F and Esteller M: Dynamic epigenetic
regulation of the microRNA-200 family mediates epithelial and
mesenchymal transitions in human tumorigenesis. Oncogene.
31:2062–2074. 2012. View Article : Google Scholar :
|
|
45
|
Enkhbaatar Z, Terashima M, Oktyabri D,
Tange S, Ishimura A, Yano S and Suzuki T: KDM5B histone demethylase
controls epithelial-mesenchymal transition of cancer cells by
regulating the expression of the microRNA-200 family. Cell Cycle.
12:2100–2112. 2013. View Article : Google Scholar : PubMed/NCBI
|
